new molecules and indications for glp 1 medicines The expanding benefits of GLP-1 GLP-1 2.0: Where the Next

Bu yan etki genellikle yksek dozlarda grlmektedir

PMID: 39178681 Acta Pharmacol Sin Activation of peripheral muscarinic receptors rescues depressive-like behaviors via gut-brain-axis, involving parasympathetic excitation

Because MIS-C has only recently been identified, the medical community is still trying to understand what causes it, as well as its long-term health consequences

North America is expected to dominate the GLP-1 receptor agonist market, accounting for 40.7% of the market share in 2026

Human clinical trials resulted in approximately 10.4% average weight loss over six months for Motus (oral), which is notable for a supplement and positions it as a strong oral option for people who prefer non-injectable approaches